Your Good Partner in Biology Research

Recombinant Human Receptor tyrosine-protein kinase erbB-2 (ERBB2), partial (Active)

In Stock
  • 货号:
    CSB-MP007763HU
  • 规格:
    ¥1368
  • 图片:
    • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
    • Activity
      Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml. Biological Activity Assay
  • 其他:

产品详情

  • 纯度:
    Greater than 95% as determined by SDS-PAGE.
  • 内毒素:
    Less than 1.0 EU/ug as determined by LAL method.
  • 生物活性:
    Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
  • 基因名:
    ERBB2
  • Uniprot No.:
  • 别名:
    (MLN 19)(Proto-oncogene Neu)(Proto-oncogene c-ErbB-2)(Tyrosine kinase-type cell surface receptor HER2)(p185erbB2)(CD340)(HER2)(MLN19)(NEU)(NGL)
  • 分子结构:
  • 种属:
    Homo sapiens (Human)
  • 蛋白长度:
    Partial
  • 来源:
    Mammalian cell
  • 分子量:
    70.2 kDa
  • 表达区域:
    23-652aa
  • 氨基酸序列
    TQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLT
  • 蛋白标签:
    C-terminal 6xHis-tagged
  • 产品提供形式:
    Lyophilized powder
    Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
  • 缓冲液:
    Lyophilized from a 0.2 μm filtered 20 mM Tris-HCl, 0.5 M NaCl, 6% Trehalose, pH 8.0
  • 复溶:
    We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
  • 储存条件:
    Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
  • 保质期:
    The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
    Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
  • 货期:
    3-7 business days
  • 注意事项:
    Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
  • 产品描述:

    CUSABIO expressed the human ERBB2 amino acid residues Met23-Thr652 carrying a C-terminal 6xHis-tag in the mammalian cells. The obtained product is the recombinant partial-length human ERBB2 protein. The purity of this protein was measured by SDS-PAGE and reached up to 95%. It migrated to a band with a molecular weight of 90 kDa on the gel under reducing conditions. And it contains less than 1.0 EU/ug endotoxin determined by the LAL method. Its bio-activity was tested through the functional ELISA. In-stock recombinant ERBB2 protein is offered now.

    ERBB2 is involved in the modulation of various vital functions, including cell growth, differentiation, and apoptosis. It is also an important player in human malignancies. Amplification or overexpression of ERBB has been reported in about 30% of human breast carcinomas and other human cancers.

  • Datasheet & COA:
    Please contact us to get it.

产品评价

平均分:
5.0分 - 3 个评价

实验应用:抗原, 结合实验/蛋白间互作

产品评价: ERBB2参与多种重要功能的调节,包括细胞生长、分化和凋亡,是人类恶性肿瘤的重要参与者,是当前研究肿瘤的热门靶点之一。我使用CSB-MP007763HU产品进行ELISA实验,EC50为1.212-3.812 ng/ml,蛋白具有完整的生物活性。后续筛选抗体获得较多优质抗体,蛋白的性能不错!后续开展实验很顺利!推荐购买~

By 周老师

实验应用:抗原, 结合实验/蛋白间互作

产品评价: 收到产品后,我们进行了SDS质控和功能ELISA验证,结果显示蛋白纯度高于标准,无杂带,与抗体的结合活性较好,EC50为1.212-3.812 ng/ml。免疫小鼠后,血清效价高,包被蛋白测试ELISA效果好。现货产品,发货快,包装好,蛋白性能稳定,可重复性好!会继续大量采购!推荐推荐~~·

By 于老师

实验应用:抗原, 结合实验/蛋白间互作

产品评价: CUSABIO的蛋白产品活性数据和纯度都挺好,介绍得很全面,服务也很不错。我们做的实验很成功,筛选的抗体特异性好,灵敏度高。后续会继续采购!

By 苏老师

靶点详情

  • 功能:
    Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.; In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.
  • 基因功能参考文献:
    1. This abnormally sensitive electrochemical sensing performance resulting from anionic porphyrin for DNA sequences specific to HER2 gene will offer considerable promise for tumor diagnosis and treatment PMID: 30340409
    2. Authors showed that mRNA and protein levels of COX2 and HER2 were upregulated in CRC compared with the adjacent tissues. COX2 protein levels and nuclear COX2 expression were correlated with a poor prognosis of CRC patients. COX2 expression was positively associated with HER2 expression. PMID: 29873317
    3. In patients with HER2-positive advanced breast cancer who have been heavily pretreated with anti-HER2 agents and cytotoxic chemotherapy, trastuzumab emtansine (T-DM1) is well tolerated and provided a meaningful progression-free survival of 6 months and an overall survival that has not been reached. PMID: 29326401
    4. The expression of C-Met and HER2 protein in lung adenocarcinoma is highly correlated, and whether it is synergistic in the targeted therapy of lung adenocarcinoma deserves further study. PMID: 29400000
    5. Although ST6GalI overexpression increased HER2 sialylation, corresponding to decreased HER2 phosphorylation, high alpha2,6sialylation enhanced Akt and ERK phosphorylation levels compared to those in the vector cell line; ST6GalI knockdown had the opposite effects. Collectively, these results implicated a functional role of ST6GalI in promoting tumor cell progression and trastuzumab resistance. PMID: 30226606
    6. Study demonstrate that the miR-495 exerts promotive effects on GC chemosensitivity via inactivation of the mTOR signaling pathway by suppressing ERBB2. The study provides reliable evidence supporting the use of miR-495 as a novel potential target in the chemotherapy of GC. PMID: 30147110
    7. In early breast cancer, PIK3CA mutations seem to identify HER2+ patients who are less likely to reach pCR. The clinical implications of PIK3CA mutations tend to vary between exon 9 and exon 20. This mechanism should be explored in further studies. PMID: 29575819
    8. HER2 and HER3 expression was detected in 22.2% and 86.1% of samples, respectively. The frequency of EGFR mutation was 45.7% and was not significantly different between stage 0 and IA1 (40.0% and 48.0%, respectively), suggesting that EGFR mutation does not correlate with cancer progression from stage 0 to IA1. PMID: 29473311
    9. It has been demonstrated that the heterogeneity of HER2 expression accelerated the development of metastases which caused the poor survival of mice with heterogeneous HER2 expression (HER2-60). PMID: 30042341
    10. Her-2/neu amplification increases with increasing grade of breast cancer. A high proportion of Her-2/neu gene amplified cases indicates aggressive disease in that area and need for FISH testing on large scale, which is the gold standard for equivocal cases on immunohistochemistry. PMID: 30060783
    11. Data indicate that the major mechanism is the ability of p140Cap to interfere with ERBB2-dependent activation of Rac GTPase-controlled circuitries. PMID: 28300085
    12. Study showed the expression levels of Gli1 and HER2 were significantly higher in gastric cancer, and they are positively related. HER2 may regulate Gli1 by Akt-mTOR-p70S6K pathway. PMID: 29321573
    13. The combination of immunohistochemical expression of BRCA1, ER, PR, and HER-2/neu and clinicopathological details may be helpful in predicting the individuals more likely to carry BRCA1 mutations and thus selecting the candidate and family members for genetic screening for BRCA1 mutations. PMID: 29567881
    14. In the current settings, HER2/neu is not found to be a prognostic marker in head-and-neck cancers. PMID: 30004046
    15. These results may be commented as HE4 expression rises in patients with HER2/neu amplification. PMID: 30004048
    16. HER2 gene amplification in circulating tumor DNA predicts HER2-positive breast neoplasms resistance to trastuzumab emtansine. PMID: 29700710
    17. Statistical analysis performed in this study did not reveal the significant relationship between HER2 overexpression on the tumor cells and microvessel density in the tumor stroma. PMID: 30334990
    18. Data showed a high rate of discordance in matched pairs of primary tumors and metastases, suggesting that the accurate evaluation of proto-oncogene protein HER-2 (HER2) status is essential before any therapeutic decision. PMID: 30203148
    19. HER2 gene amplification occurred during the early stages of gastric cancer and showed heterogeneity in several cases. HER2 gene amplification may be involved in tumor progression in early gastric cancer. PMID: 30120594
    20. Activating HER2 mutation is present in about 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer. PMID: 30094493
    21. The results suggested a possible link between tRNALeu overexpression and RSK1/MSK2 activation and ErbB2/ErbB3 signaling, especially in breast cancer. PMID: 28816616
    22. High HER2 expression is associated with metastasis in breast Cancer. PMID: 29187405
    23. This study confirmed that biosimilar trastuzumab improves the overall response rate when combined with chemotherapy for HER2+ breast cancer PMID: 30082554
    24. The Authors reveal a gender difference in the prognostic value of concomitant AIB1 and HER2 copy number gain (CNG) in glioma patients which were barely noticed before. These observations indicated that genetic alterations synergistic with essential respects of sex determination influence glioma biology and patients outcomes. PMID: 30153912
    25. The survival rates in this study are equal to the documented global rates; nodal disease burden emerged as the most important prognostic factor. In addition, in EBCs, a lack of hormone receptor expression and in LABC, Her2neu overexpression appear to worsen the outcome. PMID: 30147088
    26. Results showed that HER2 and FGFR2 are regulated by DDX6 at the post-transcriptional step in gastric cancer. PMID: 29987267
    27. HER2 overexpression is associated with Gastric Cancer. PMID: 29938472
    28. ERBB2 oncogene at 17q12 is susceptible to palindromic gene amplification in HER2-positive breast tumors. PMID: 28211519
    29. Results show mutation in ERBB2-exon17 was associated with worse survival results in patients with pancreatic neoplasm. [review] PMID: 30227250
    30. High HER2 expression and Gene Amplification is associated with Upper Tract Urothelial Carcinomas. PMID: 28755093
    31. High HER2 expression is associated with invasion and lymph node metastasis in gastric cancer. PMID: 29970682
    32. Basal HER2 phenotype showed poor DFS, but equivalent pCR rate after concurrent neo-adjuvant chemotherapy with trastuzumab. A different treatment approach to basal-HER2 type is needed even for cases that achieved adequate clinical response after neo-adjuvant chemotherapy. PMID: 29971625
    33. In the largest series reported to date, patients with HER2-amplified m17 cancers treated with trastuzumab have outcomes comparable to patients from the large phase III adjuvant trastuzumab trials who were HER2-positive, supporting the critical role of HER2-directed therapy in this patient population. PMID: 28986743
    34. The interplay of dual MET/HER2 overexpression in the AKT and ERK pathways for esophageal cancer is described. Therefore, combination therapy could be a novel strategy for EAC with amplification of both MET and HER2. PMID: 29223420
    35. Study provides evidence that the hostile environment developed in spheroids has a key role in the acquisition of resistance to Trastuzumab and is associated with an increase in the number of breast cancer stem cells as well as a modulation in HER2 expression. PMID: 28722778
    36. A major finding of our study is that one out of five (20%) patients with breast cancer BM had a receptor discrepancy between the primary tumor and the subsequent BM, with loss of hormone receptors (ER and/or PR) expression, and gain of HER2 overexpression as the most commonly observed changes PMID: 28975433
    37. High HER2 expression is associated with Gastric Adenocarcinoma. PMID: 29802704
    38. Absence of HER2 Expression of Circulating Tumor Cells is associated with Non-Metastatic Esophageal Cancer. PMID: 30275185
    39. HER2 positivity was found in a minority of rectal cancer patients and was not significantly associated with clinicopathologic and molecular characteristics. PMID: 30056472
    40. Study discovered a novel enhancer HER2 gene body enhancer (HGE) in the 3' gene body of HER2. The HGE activates promoters 1 and 2 in trans., and hence the TFAP2C-mediated transcriptional induction of HER2 expression in breast cancer samples. PMID: 29035388
    41. ctDNA gene mutation profiles differed among HR/HER2 subtypes of metastatic breast cancer (MBC) patients. By identifying mutations associated with treatment resistance, we hope to improve therapy selection for MBC patients who received multiline treatment. PMID: 29807833
    42. It was concluded that miR494 inhibited the cancer initiating cells phenotype and reversed resistance to lapatinib by inhibiting FGFR2 in HER2positive gastric cancer. PMID: 29786108
    43. HER2 overexpression was evident in nearly 25% of the Malaysian patients with locally advanced or metastatic gastric cancer. The overexpression correlated significantly with male gender and diffuse-type tumors. PMID: 28124769
    44. There was a statistically significant association between positive p95-HER2 expression and negative hormonal receptors expression (p=0.004), high Ki-67 expression (p<0.001) and development of visceral metastasis PMID: 29779938
    45. The authors herein prove, for the first time, that the transcriptional repressor Blimp1 is a novel mediator of p130Cas/ErbB2-mediated invasiveness. Indeed, high Blimp1 expression levels are detected in invasive p130Cas/ErbB2 cells and correlate with metastatic status in human breast cancer patients. PMID: 28442738
    46. ERBB2 amplification is driving resistance to erlotinib in lung adenocarcinoma. PMID: 28870636
    47. Results showed that combining the results of IHC and FISH according to the HER2 testing algorithm is a useful method for accurately evaluating HER2-positive EMPD. PMID: 29744813
    48. Because the concordance rates of HER2 IHC score 2/3+ cases were lower than that of HER2 IHC score 0/1+ cases, further studies for detailed analysis criteria for HER2 IHC score 2+ or 3+ are required. PMID: 28478639
    49. HER2 interacts with Beclin 1 in breast cancer cells and inhibits autophagy. Mice with increased basal autophagy due to a genetically engineered mutation in Becn1 are protected from human HER2-driven mammary tumorigenesis. HER2-mediated inhibition of Beclin 1 and autophagy likely contributes to HER2-mediated tumorigenesis. PMID: 29610308
    50. These findings suggest that early-stage morphological alterations of HER2-positive BC cells during cancer progression can occur in a physical and signalling-independent manner. PMID: 27599456

    显示更多

    收起更多

  • 相关疾病:
    Glioma (GLM); Ovarian cancer (OC); Lung cancer (LNCR); Gastric cancer (GASC)
  • 亚细胞定位:
    [Isoform 1]: Cell membrane; Single-pass type I membrane protein. Early endosome. Cytoplasm, perinuclear region. Nucleus.; [Isoform 2]: Cytoplasm. Nucleus.; [Isoform 3]: Cytoplasm. Nucleus.
  • 蛋白家族:
    Protein kinase superfamily, Tyr protein kinase family, EGF receptor subfamily
  • 组织特异性:
    Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth.
  • 数据库链接:

    HGNC: 3430

    OMIM: 137800

    KEGG: hsa:2064

    STRING: 9606.ENSP00000269571

    UniGene: Hs.446352